










CLAIMS

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:






(I);



wherein:


A is selected from the group consisting of , , , , , , , , , , , ,

- 305 -







, and ;







B is selected from the group consisting of










indicates the point of attachment to C;





 is selected from the group consisting of , ; and



C is selected from the group consisting of , , , , , .




2. The compound of claim 1, wherein (B) is .

3. The compound of claim 1 or 2, wherein  is .

4. The compound of any one of claims 1-3, wherein (C) is selected from the group consisting of , , , and .




5. The compound of claim 4, wherein C is  or .


6. A compound of formula (II), or a pharmaceutically acceptable salt thereof:


























(II);


wherein:



A is selected from the group consisting of , , .






,

,

,

,

, and

;


B is selected from the group consisting of

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



, and ;; wherein the asterisk (*) indicates the point of attachment to C;



is selected from the group consisting of ,




, and ; and





C is selected from the group consisting of ,








7. The compound of claim 6, wherein (A) is .

8. The compound of claim 6 or 7, wherein  is .

9. The compound of any one of claims 6-8, wherein  is selected from the group consisting of , , , and .



10. The compound of claim 9, wherein  is  or .


11. A compound of formula (III), or a pharmaceutically acceptable salt thereof:


























(III);
















wherein:


 is selected from the group consisting of , ,





































,

,

,

,

, and

;


B is selected from the group consisting of

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


















; wherein the asterisk (*) indicates the point of attachment to (C);


 is selected from the group consisting of , ,



, , , and ; and

C is selected from the group consisting of , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , .




12. The compound of claim 11, wherein A is , or .

13. The compound of claim 11 or 12, wherein B is .

14. The compound of any one of claims 11-13, wherein  is .


15. A compound of formula (IV), or a pharmaceutically acceptable salt thereof:





(IV);


wherein:























is selected from the group consisting of 









































,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and


;




B is selected from the group consisting of , , , , , , , , , , , , , , , , , , , , , , , , , , .



, and ; wherein the asterisk (*) indicates the point of attachment to C;






is selected from the group consisting of , and ; and



C is selected from the group consisting of ,












16. The compound of claim 15, wherein A is , , or .









17. The compound of claim 15 or 16, wherein B is .









18. The compound of any one of claims 15-17, wherein C is selected from the group consisting of , , , and .









19. The compound of claim 18, wherein C is  or .









20. A compound, or a pharmaceutically acceptable salt thereof, selected from the following table:









	
	
	
	 (+)-isomer









	 (-)-isomer
	
	
	









	
	
	
	











	
	
	
	









	
	 (-)-isomer
	
	









	
	
	
 (+)-isomer	






	
	
	
	



	
	
	
	 (+)-isomer











	
	
	
	









	
	
 (-)-isomer	









.









21. A compound, or a pharmaceutically acceptable salt thereof, selected from the following table:











	









	
	
	
	
	


	
	
	
	

 wherein R' is methyl, propyl, isopropyl, isobutyl, cyclopropyl, or cyclobutyl	
	
	
	

.

22. A pharmaceutical composition, comprising a compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

23. Use of a compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

24. The use of claim 23, wherein the disease or condition characterized by aberrant complement system activity is an immunological disorder.

25. The use of claim 23, wherein the disease or condition characterized by aberrant complement system activity is a disease of the central nervous system.

26. The use of claim 23, wherein the disease or condition characterized by aberrant complement system activity is a neurodegenerative disease or neurological disease.

27. The use of claim 23, wherein the disease or condition characterized by aberrant complement system activity is a renal disease.

28. The use of claim 23, wherein the disease or condition characterized by aberrant complement system activity is a cardiovascular disease.

29. The use of claim 23, wherein the disease or condition characterized by aberrant complement system activity is selected from the group consisting of paroxysmal

nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, organ transplant rejection, myasthenia gravis, neuromyelitis optica, membranoproliferative glomerulonephritis, dense-deposit disease, cold agglutinin disease, and catastrophic antiphospholipid syndrome.

30. The use of claim 23, wherein the disease or condition characterized by aberrant complement system activity is selected from the group consisting of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), warm autoimmune hemolytic anemia, IgA nephropathy, C3 glomerulonephritis, and focal segmental glomerulosclerosis.

31. The use of claim 23, wherein the disease or condition characterized by aberrant complement system activity is a hematological disorder.

32. The use of claim 23, wherein the disease or condition characterized by aberrant complement system activity is an ocular disorder or an eye disorder.

33. The use of claim 23, wherein the disease or condition characterized by aberrant complement system activity is macular degeneration, age-related macular degeneration (AMD), macular edema, diabetic macular edema, choroidal neovascularization (CNV), uveitis, Behcet's uveitis, proliferative diabetic retinopathy, non-proliferative diabetic retinopathy, glaucoma, hypertensive retinopathy, a corneal neovascularization disease, post-corneal transplant rejection, a corneal dystrophic disease, an autoimmune dry eye disease, Stevens-Johnson syndrome, Sjogren's syndrome, an environmental dry eye disease, Fuchs' endothelial dystrophy, retinal vein occlusion, or post-operative inflammation.

34. The use of claim 23, wherein the disease or condition characterized by aberrant complement system activity is paroxysmal nocturnal hemoglobinuria.

35. A compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, for use in therapy.